VanEck Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.7M | Buy |
65,332
+2,748
| +4% | +$1.87M | 0.02% | 320 |
|
|
2026
Q1 | $48.4M | Sell |
62,584
-2,311
| -4% | -$1.77M | 0.04% | 275 |
|
|
2025
Q4 | $50.1M | Buy |
64,895
+8,377
| +15% | +$5.69M | 0.04% | 246 |
|
|
2025
Q3 | $31.8M | Sell |
56,518
-1
| -0% | -$565 | 0.03% | 282 |
|
|
2025
Q2 | $29.7M | Buy |
56,519
+1,292
| +2% | +$721K | 0.03% | 283 |
|
|
2025
Q1 | $35M | Sell |
55,227
-3,306
| -6% | -$2.27M | 0.05% | 235 |
|
|
2024
Q4 | $41.7M | Buy |
58,533
+397
| +0.7% | +$333K | 0.05% | 197 |
|
|
2024
Q3 | $54.7M | Buy |
58,136
+4,742
| +9% | +$5.28M | 0.07% | 171 |
|
|
2024
Q2 | $56.1M | Sell |
53,394
-1,945
| -4% | -$1.89M | 0.08% | 161 |
|
|
2024
Q1 | $53.3M | Sell |
55,339
-8,998
| -14% | -$8.56M | 0.08% | 155 |
|
|
2023
Q4 | $56.5M | Buy |
64,337
+7,509
| +13% | +$6.18M | 0.1% | 140 |
|
|
2023
Q3 | $46.8M | Sell |
56,828
-3,387
| -6% | -$2.66M | 0.1% | 150 |
|
|
2023
Q2 | $43.3M | Buy |
60,215
+1,445
| +2% | +$1.11M | 0.09% | 159 |
|
|
2023
Q1 | $48.3M | Buy |
58,770
+7,267
| +14% | +$5.48M | 0.11% | 152 |
|
|
2022
Q4 | $37.2M | Sell |
51,503
-15,153
| -23% | -$11.2M | 0.1% | 169 |
|
|
2022
Q3 | $45.9M | Buy |
66,656
+3,130
| +5% | +$1.97M | 0.14% | 146 |
|
|
2022
Q2 | $37.6M | Buy |
63,526
+470
| +0.7% | +$306K | 0.1% | 183 |
|
|
2022
Q1 | $44M | Sell |
63,056
-2,242
| -3% | -$1.42M | 0.09% | 184 |
|
|
2021
Q4 | $41.2M | Buy |
65,298
+4,787
| +8% | +$2.94M | 0.1% | 178 |
|
|
2021
Q3 | $36.6M | Sell |
60,511
-5,089
| -8% | -$3.16M | 0.09% | 192 |
|
|
2021
Q2 | $36.6M | Buy |
65,600
+3,649
| +6% | +$1.85M | 0.09% | 191 |
|
|
2021
Q1 | $29.3M | Buy |
61,951
+3,777
| +6% | +$1.84M | 0.08% | 187 |
|
|
2020
Q4 | $28.1M | Buy |
58,174
+8,928
| +18% | +$4.82M | 0.08% | 182 |
|
|
2020
Q3 | $27.6M | Buy |
49,246
+4,369
| +10% | +$2.65M | 0.09% | 147 |
|
|
2020
Q2 | $28M | Buy |
44,877
+7,489
| +20% | +$4.25M | 0.1% | 149 |
|
|
2020
Q1 | $18.3M | Sell |
37,388
-13,966
| -27% | -$5.76M | 0.09% | 150 |
|
|
2019
Q4 | $19.3M | Sell |
51,354
-1,073
| -2% | -$361K | 0.07% | 180 |
|
|
2019
Q3 | $14.5M | Buy |
52,427
+816
| +2% | +$241K | 0.07% | 185 |
|
|
2019
Q2 | $16.2M | Buy |
51,611
+3,799
| +8% | +$1.26M | 0.08% | 182 |
|
|
2019
Q1 | $19.6M | Sell |
47,812
-5,233
| -10% | -$2.15M | 0.1% | 160 |
|
|
2018
Q4 | $19.8M | Sell |
53,045
-5,923
| -10% | -$2.17M | 0.1% | 166 |
|
|
2018
Q3 | $23.8M | Buy |
58,968
+814
| +1% | +$310K | 0.12% | 163 |
|
|
2018
Q2 | $20.1M | Sell |
58,154
-2,910
| -5% | -$910K | 0.09% | 175 |
|
|
2018
Q1 | $21M | Sell |
61,064
-8,479
| -12% | -$2.95M | 0.1% | 159 |
|
|
2017
Q4 | $26.1M | Sell |
69,543
-2,798
| -4% | -$1.13M | 0.13% | 157 |
|
|
2017
Q3 | $32.3M | Buy |
72,341
+5,454
| +8% | +$2.6M | 0.17% | 128 |
|
|
2017
Q2 | $32.9M | Sell |
66,887
-14,536
| -18% | -$6.36M | 0.18% | 100 |
|
|
2017
Q1 | $31.6M | Buy |
81,423
+10,479
| +15% | +$3.88M | 0.14% | 118 |
|
|
2016
Q4 | $26M | Buy |
70,944
+3,567
| +5% | +$1.36M | 0.13% | 114 |
|
|
2016
Q3 | $27.1M | Sell |
67,377
-1,902
| -3% | -$763K | 0.13% | 108 |
|
|
2016
Q2 | $24.2M | Buy |
69,279
+1,285
| +2% | +$495K | 0.12% | 102 |
|
|
2016
Q1 | $24.5M | Buy |
67,994
+6,301
| +10% | +$2.6M | 0.17% | 112 |
|
|
2015
Q4 | $33.5M | Sell |
61,693
-7,071
| -10% | -$3.83M | 0.27% | 94 |
|
|
2015
Q3 | $32M | Sell |
68,764
-8,006
| -10% | -$4.3M | 0.25% | 102 |
|
|
2015
Q2 | $39.2M | Sell |
76,770
-13,570
| -15% | -$6.62M | 0.23% | 114 |
|
|
2015
Q1 | $40.8M | Buy |
90,340
+22,008
| +32% | +$9.33M | 0.24% | 106 |
|
|
2014
Q4 | $28M | Sell |
68,332
-833
| -1% | -$328K | 0.17% | 123 |
|
|
2014
Q3 | $24.9M | Sell |
69,165
-2,785
| -4% | -$933K | 0.13% | 132 |
|
|
2014
Q2 | $20.3M | Sell |
71,950
-22,314
| -24% | -$6.61M | 0.09% | 143 |
|
|
2014
Q1 | $28.3M | Buy |
94,264
+19,542
| +26% | +$6.02M | 0.14% | 122 |
|
|
2013
Q4 | $20.6M | Sell |
74,722
-2,931
| -4% | -$843K | 0.1% | 135 |
|
|
2013
Q3 | $24.3M | Buy |
77,653
+16,910
| +28% | +$4.45M | 0.12% | 104 |
|
|
2013
Q2 | $13.7M | Buy |
+60,743
| New | +$14.1M | 0.07% | 124 |
|
Other funds holding REGN
VanEck Associates's REGN Position: Q2 2026 in Review
VanEck Associates increased its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2026, buying an estimated $1.87M and bringing the position to 65,332 shares worth $40.7M. The position accounts for 0.02% of the portfolio, ranked #320.
VanEck Associates first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $56.5M in Q4 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- VanEck Associates held 65,332 shares of Regeneron Pharmaceuticals worth $40.7M as of Q2 2026.
- VanEck Associates bought 2,748 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.87M.
- Regeneron Pharmaceuticals made up 0.02% of VanEck Associates's portfolio in Q2 2026, its #320 holding.
- VanEck Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- VanEck Associates's Regeneron Pharmaceuticals position peaked at $56.5M in Q4 2023.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.